Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of i...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full |
| _version_ | 1797978611914899456 |
|---|---|
| author | Nur Olgun Emre Cecen Dilek Ince Deniz Kizmazoglu Birsen Baysal Ayse Onal Ozhan Ozdogan Handan Guleryuz Riza Cetingoz Ayse Demiral Mustafa Olguner Ahmet Celik Serra Kamer Erdener Ozer Zekiye Altun Safiye Aktas |
| author_facet | Nur Olgun Emre Cecen Dilek Ince Deniz Kizmazoglu Birsen Baysal Ayse Onal Ozhan Ozdogan Handan Guleryuz Riza Cetingoz Ayse Demiral Mustafa Olguner Ahmet Celik Serra Kamer Erdener Ozer Zekiye Altun Safiye Aktas |
| author_sort | Nur Olgun |
| collection | DOAJ |
| description | BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of immunotherapy with dinutuximab beta (DB) and chemotherapy in patients with relapsed/refractory high-risk neuroblastoma.MethodsAll patients received the Turkish Pediatric Oncology Group NB 2009 national protocol for HR-NB treatment at the time of diagnosis. Salvage treatments were administered after progression or relapse. The patients who could not achieve remission in primary or metastatic sites were included in the study. The most common chemotherapy scheme was irinotecan and temozolomide. DB was administered intravenously for 10 days through continuous infusion with 10 mg/m2 per day. The patients received 2 to 14 successive cycles with duration of 28 days each. Disease assessment was performed after cycles 2, 4, and 6 and every 2 to 3 cycles thereafter.ResultsBetween January 2020 and March 2022, nineteen patients received a total of 125 cycles of DB and chemotherapy. Objective responses were achieved in 12/19 (63%) patients, including complete remission in 6/19 and partial response in 6/19. Stable disease was observed in two patients. The remaining five patients developed bone/bone marrow and soft tissue progression after 2-4 cycles of treatment. The most common Grade ≥3 toxicities were leukopenia, thrombocytopenia, hypertransaminasemia, fever, rash/itching and capillary leak syndrome, respectively.ConclusionOur study results suggest that DB-based chemo-immunotherapy seems to be suitable with encouraging response rates in patients with relapsed/refractory high-risk neuroblastoma. |
| first_indexed | 2024-04-11T05:25:43Z |
| format | Article |
| id | doaj.art-1b24bfd89ea64c6582e6ec8ecea02eff |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T05:25:43Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1b24bfd89ea64c6582e6ec8ecea02eff2022-12-23T06:59:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.10414431041443Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experienceNur Olgun0Emre Cecen1Dilek Ince2Deniz Kizmazoglu3Birsen Baysal4Ayse Onal5Ozhan Ozdogan6Handan Guleryuz7Riza Cetingoz8Ayse Demiral9Mustafa Olguner10Ahmet Celik11Serra Kamer12Erdener Ozer13Zekiye Altun14Safiye Aktas15Department of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Pediatric Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Nuclear Medicine, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Radiology, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Radiation Oncology, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Radiation Oncology, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Pediatric Surgery, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Pediatric Surgery, Ege University School of Medicine, Izmir, TürkiyeDepartment of Radiation Oncology, Ege University School of Medicine, Izmir, TürkiyeDepartment of Pathology, Dokuz Eylul University School of Medicine, Izmir, TürkiyeDepartment of Basic Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeDepartment of Basic Oncology, Dokuz Eylul University Institute of Oncology, Izmir, TürkiyeBackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of immunotherapy with dinutuximab beta (DB) and chemotherapy in patients with relapsed/refractory high-risk neuroblastoma.MethodsAll patients received the Turkish Pediatric Oncology Group NB 2009 national protocol for HR-NB treatment at the time of diagnosis. Salvage treatments were administered after progression or relapse. The patients who could not achieve remission in primary or metastatic sites were included in the study. The most common chemotherapy scheme was irinotecan and temozolomide. DB was administered intravenously for 10 days through continuous infusion with 10 mg/m2 per day. The patients received 2 to 14 successive cycles with duration of 28 days each. Disease assessment was performed after cycles 2, 4, and 6 and every 2 to 3 cycles thereafter.ResultsBetween January 2020 and March 2022, nineteen patients received a total of 125 cycles of DB and chemotherapy. Objective responses were achieved in 12/19 (63%) patients, including complete remission in 6/19 and partial response in 6/19. Stable disease was observed in two patients. The remaining five patients developed bone/bone marrow and soft tissue progression after 2-4 cycles of treatment. The most common Grade ≥3 toxicities were leukopenia, thrombocytopenia, hypertransaminasemia, fever, rash/itching and capillary leak syndrome, respectively.ConclusionOur study results suggest that DB-based chemo-immunotherapy seems to be suitable with encouraging response rates in patients with relapsed/refractory high-risk neuroblastoma.https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/fullneuroblastomarelapsedrefractorydinutuximab betaanti-GD2 |
| spellingShingle | Nur Olgun Emre Cecen Dilek Ince Deniz Kizmazoglu Birsen Baysal Ayse Onal Ozhan Ozdogan Handan Guleryuz Riza Cetingoz Ayse Demiral Mustafa Olguner Ahmet Celik Serra Kamer Erdener Ozer Zekiye Altun Safiye Aktas Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience Frontiers in Oncology neuroblastoma relapsed refractory dinutuximab beta anti-GD2 |
| title | Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience |
| title_full | Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience |
| title_fullStr | Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience |
| title_full_unstemmed | Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience |
| title_short | Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience |
| title_sort | dinutuximab beta plus conventional chemotherapy for relapsed refractory high risk neuroblastoma a single center experience |
| topic | neuroblastoma relapsed refractory dinutuximab beta anti-GD2 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full |
| work_keys_str_mv | AT nurolgun dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT emrececen dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT dilekince dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT denizkizmazoglu dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT birsenbaysal dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT ayseonal dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT ozhanozdogan dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT handanguleryuz dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT rizacetingoz dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT aysedemiral dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT mustafaolguner dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT ahmetcelik dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT serrakamer dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT erdenerozer dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT zekiyealtun dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience AT safiyeaktas dinutuximabbetaplusconventionalchemotherapyforrelapsedrefractoryhighriskneuroblastomaasinglecenterexperience |